We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Christian Pavlovich

Christian P. Pavlovich MD

Professor of Urology and Oncology; Director of Urologic Oncology Fellowship, Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland

Dr. Pavlovich has been on staff at Johns Hopkins in the Department of Urology since 2001. He is Director of Urologic Oncology at the Johns Hopkins Bayview Medical Center and Director of the Johns Hopkins Urologic Oncology Fellowship Program. His practice is dedicated primarily to the treatment of prostate, kidney and bladder cancer, as well as to the treatment of benign prostatic diseases. He is experienced in open, laparoscopic, and robotic minimally invasive surgery for the management of urologic tumors, including nerve-sparing laparoscopic and robotic- assisted radical prostatectomy, laparoscopic and robotic nephrectomy and partial nephrectomy, and robotic radical cystectomy. A particular expertise of his is the robotic extraperitoneal (or retroperitoneal) approach to the prostate and kidney for patients with prostate or kidney cancer. This approach, which avoids entry into the abdominal cavity, is ideally suited for patients that have had prior abdominal or inguinal operations (e.g. hernia repairs, appendectomy, colectomy) or who have inflammatory conditions (e.g. Crohn’s disease, ulcerative colitis, diverticulitis) or obesity that might make an abdominal robotic approach more hazardous.

Dr. Pavlovich’s research has been funded by the National Institutes of Health, Department of Defense, industry, and through institutional grants.  He continues to work on early detection and risk stratification of prostate and kidney cancer using novel urinary, blood, and imaging modalities. As Director of Urologic Oncology at Johns Hopkins Bayview Medical Center, he continues to treat cancer with an emphasis on minimizing morbidity and maximizing quality of life, while exposing his patients to the latest treatment options and techniques. In addition, as Fellowship Director for Urologic Oncology, he oversees the selection and training of the next generation of leaders in the field.